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INTRODUCTION
Tumors angiogenesis is aberrant regulation of angiogenesis in
solid cancers. It is an important process required for invasion and
metastasis (1-4). Although it is not completely clarified, the com-
plex process of tumor angiogenesis is regulated by multiple signal-
ing pathways. The proangiogenic multiple pathways include VEGF
and VEGF receptor (VEGF-R), FGF and FGF receptor (FGF-R),
and PDGF and PDGF receptor (PDGF-R) pathways in vascular
endothelial cells (5). In addition to endothelial cells, tumor cells not
only produce VEGF, FGF and PDGF, but also express VEGF-R,
FGF-R and PDGF-R, suggesting roles for autocrine and paracrine
activation of those signaling pathways in cancer cells (5).
In the advanced solid tumors, recent antiangiogenic chemo-
therapies have focused on blocking simultaneously the multiple
proangiogenic signaling pathways. Several currently available an-
tiangiogenic treatments aim to inhibit VEGF/VEGF-R, FGF/FGF-
R and PDGF/PDGF-R pathways. For example, regorafenib is a
multiple receptor tyrosine kinase inhibitor (RTKI) that simultane-
ously inhibits the VEGF-R, FGF-R and PDGF-R (6, 7), suggesting
that the multiple RTKIs affect not only vascular endothelial cells but
also cancer cells. However, direct effects of the RTKIs on tumor
cells remain unclear.
Regorafenib was approved by the FDA in 2012 for the second-
line treatment of metastatic colorectal cancer patients. In a pivotal
randomizedphase III study of regorafenib treatment, a statistically
significant prolongation in overall survival was observed in patients
with colorectal cancer who received regorafenib therapy (6, 7).
Despite the survival benefit of regorafenib for metastatic colorectal
cancer patients, its overall clinical efficacy remains quite limited.
Unfortunately, the vast majority of patients who initially respond to
the agent will develop resistance (8-10).
The central mechanism of the resistance to multiple RTKIs is
considered to be hypoxic stress induced by disruption of tumor
angiogenesis (10-12). In addition to hypoxia, we previously dem-
onstrated that regorafenib directly acted on colorectal cancer cells
and accelerated their malignant phenotypes, including apoptosis
resistance and migration activation, in a hypoxia- independent
manner (13).
Thus, the aim of this study is to elucidate how regorafenib in-
duced the malignant phenotypes in colorectal cancer cells. By
using a potent selective inhibitor for VEGF-R, FGF-R or PDGF-R,
we clarified that blockade of VEGF-R, but not FGF-R and PDGF-R,
expressed on colorectal cancer cells induced apoptosis resistance
and migration activation.
MATERIALS AND METHODS
Cell culture and treatment
Human colorectal cancer cell line (HCT116) was maintained in
RPMI1640 medium with 5% fetal bovine serum and antibiotics.
Based on our previous reports (13, 14), in order to inhibit angio-
genic receptors, cells were continuously treated for 14 days with a
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potent selective inhibitor of VEGF-R (KRN633, Selleckchem) at 40
nM, FGF-R (AZD4547, Selleckchem) at 1 nM, PDGF-R (CP-
673451, Selleckchem) at 10 nM or vehicle DMSO (0.01%). In
order to block VEGF ligands, cells were continuously treated with
recombinant soluble VEGF-R1 protein plus soluble VEGF-R3 pro-
teins (250 ng/ml each) (R&D Biosystems) or control bovine serum
albumin (500 ng/ml) for 7 days.
For hypoxic culture conditions, cells were incubated at low con-
fluence and 37 in RPMI1640 medium supplemented with HEPES
buffer (pH 7.4) using an AnaeroPack-Kenki 5% anaerobic system
in which O2 was ~0.2% (Sugiyamagen, Japan).
Cell migration assay
Equal numbers (50,000 cells per well) of cells were suspended in
0.25 ml of 1% RPMI1640FBS without or with regorafenib and
placed in the top compartment of a 8 µm pore membrane chambers
(BD Biosciences) ; 0.75 ml of 10% RPMI1640FBS was added to
the bottom compartment. Following 24-h incubation under stan-
dard conditions (37/5% CO2), non-migrating cells were scraped
from the top compartment, and cells that had migrated to the
bottom compartment were fixed and stained using the Hemacolor
Rapid staining of blood smear (Merck). Membranes were excised
and mounted on a standard microscope slide. The numbers of
migrated cells were determined from ten random high-power
fields (HPF) visualized at × 200 magnification.
Assessment of apoptosis
Apoptotic cells were assessed by imaging of activated caspase 3/7
using CellEvent caspase-3/7 green detection reagent (Molecular
probes), according to the manufacturer’s instruction.
Statistical analysis
Results are expressed as meansS.D. Statistical analyses of
data were done using ANOVA and the Scheffé’s test. P values0.05
was considered significant.
RESULTS
Effect of inhibition of regorafenib-targeting proangiogenic re-
ceptors on migration ability
In order to elucidate how a multiple RTKI regorafenib, which
inhibits simultaneously VEGF-R, FGF-R and PDGF-R, induced
activation of colorectal cancer cell migration (13), we first exam-
ined the effect of a single inhibition of the respective receptors on
cellular motility. We used a small molecule agent targeting tyrosine
kinase of VEGF-R (KRN633), FGF-R (AZD4547) or PDGF-R (CP-
673451). As shown in Figure 1, inhibition of VEGF-R markedly
activated the migration ability, compared to the DMSO-treated
control cells. By contrast, blockade of FGF-R and PDGF-R signifi-
cantly decreased the ability (Fig. 1).
Effect of inhibition of regorafenib-targeting proangiogenic re-
ceptors on apoptosis under hypoxic conditions
We then examined the effect of the single inhibition of VEGF-R,
FGF-R or PDGF-R on apoptosis under hypoxic conditions. We
chose hypoxic stress, since angiogenic inhibitors induce hypoxia
within tumor microenvironment via disruption of tumor neoangio-
genesis (1). Inhibition of VEGF-R induced apoptosis resistance,
compared to the DMSO-treated control cells (Fig. 2). Blockade of
FGF-R significantly increased apoptosis rate, compared to the
DMSO-treated control cells (Fig. 2). Under PDGF-R inhibited
conditions, the apoptosis rate was similar to the control (Fig. 2).
Effect of blocking of autocrine/paracrine VEGF signals on the
malignant phenotypes of colorectal cancer cells
It is previously reported that HCT116 cells express VEGF ligands
(VEGF, PlGF, VEGF-B, VEGF-C and VEGF-D) (14, 18). To dem-
onstrate whether blocking of autocrine and paracrine VEGF signal-
ing pathway induced the migration activation and apoptosis resis-
tance in colorectal cancer cells, we blocked all of VEGF ligands
using recombinant proteins of soluble VEGF-R1 and soluble
VEGF-R3. Soluble VEGF-R1 protein captures VEGF, PlGF and
VEGF-B, and soluble VEGF-R3 protein traps VEGF-C and VEGF-
D, thus leading to prevention of all VEGF-R activation. As similarly to
inhibition of VEGF-R by KRN633 (Fig. 1 and 2), neutralization of
Figure 1. Effect of inhibition of regorafenib- targeting proangiogenic
receptors on migration ability of colorectal cancer cells
Cells were treated with a VEGF-R inhibitor (KRN633), FGF-R inhibitor
(AZD4547), PDGF-R inhibitor (CP-673451) or vehicle (DMSO). Then
cells were used for transwell migration assay in the presence of the re-
spective inhibitor (n=4, meansSD). *P0.01 indicates the increased
migration activity compared with the DMSO-treated control cells
(vehicle). #P0.01 indicates the decreased migration activity compared
with the DMSO-treated control cells (vehicle). HPF, high power field.
Figure 2. Effect of inhibition of regorafenib- targeting proangiogenic
receptors on apoptosis under hypoxic conditions
Cells were treated with a VEGF-R inhibitor (KRN633), FGF-R inhibitor
(AZD4547), PDGF-R inhibitor (CP-673451) or vehicle (DMSO). Then
cells were exposed to hypoxia ( 0.2% O2) for additional 24 h in the
presence of the respective inhibitor. Apoptotic cells were determined by
measuring of activated caspase 3/7 (n=4, meansSD). *P0.01 indi-
cates the increased apoptosis rate compared with the DMSO-treated
control cells (vehicle). #P0.01 indicates the decreased apoptosis rate
compared with the DMSO-treated control cells (vehicle).
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VEGF ligands induced the migration activation and the apoptosis
resistance (Fig. 3A and B).
DISCUSSION
In this study, we revealed how a multiple RTKI regorafenib
accelerated the malignant phenotypes in colorectal cancer cells.
Our results show that inhibition of autocrine and paracrine VEGF/
VEGF-R signaling pathway in colorectal cancer cells induced the
phenotypes. By contrast, blockade of FGF-R and PDGF-R re-
pressed the phenotypes, consistent with previous reports (15,16).
Our results are supported by several reports using VEGF and
VEGF-R blockers (14, 17-22). Recently, there is accumulating evi-
dence that several VEGF/VEGF-R targeting antiangiogenic agents
act not only on vascular endothelial cells, but also on tumor cells, as
cancer cells also express VEGF-R (17). When the agents act on
endothelial cells, tumor vascularization is significantly inhibited,
leading to tumor regression. By contrast, when act on tumor cells,
the aggressiveness of cancer cells is increased (17). For example, a
neutralizing anti -VEGF monoclonal antibody (bevacizumab) has
been shown to stimulate the expression of tumor invasion associ-
ated factors, such as matrix metalloproteases and promoting inva-
siveness both in vitro and in vivo in glioblastoma, renal cell carci-
noma and colorectal cancer models (14, 18, 19). VEGF-R inhibitors
stimulate the expression of genesassociated with invasion and me-
tastasis, such as Snail, Slug, Fak and Axl, leading to local invasion
and distant metastasis (20-22). By contrast, inhibition of FGF-R
and PDGF-R expressed on several cancer cells suppresses the
evasive phenotypes of them (15, 16). These reports support our
finding that blockade of tumor cell VEGF-R, but not FGF-R and
PDGF-R, accelerated aggressiveness of cancer cells. In addition,
these results suggest that it might be better not to block the VEGF/
VEGF-R signaling in several cancer cells.
Collectively, we conclude that multi RTKI regorafenib induced
the malignant phenotypes of colorectal cancer cells via inhibiting of
VEGF/VEGF-R pathway. Currently, nine antiangiogenic multiple
RTKIs (regorafenib, lenvatinib, nintedanib, cabozantinib, axitinib,
vandetanib, sunitinib, sorafenib and pazopanib) are approved by
FDA for treatment of patients with several advanced cancers, in-
cluding colorectal cancer (5). Importantly, all of these approved
RTKIs have an inhibitory activity of VEGF-R, suggesting that all
the RTKIs possibly activate cancer cell aggressiveness. Thus, it will
be needed to clarify precise molecular mechanisms and a complete
understanding of the direct effects of the antiangiogenic RTKIs on
tumor cells. The elucidation can bring insights into counteracting
tumor adaptive refractoriness to the antiangiogenic drugs.
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